Literature DB >> 29604561

Effect of phospholipid coating on the migration of plasticizers from PVC tubes.

Frank Münch1, Christine Höllerer2, André Klapproth1, Elisabeth Eckert2, André Rüffer1, Robert Cesnjevar1, Thomas Göen3.   

Abstract

Plasticizers in polyvinyl chloride (PVC) are not covalently bound to the polymer and can thus migrate into the contact medium. The presented study investigated the potential effects of phospholipid-lining as anti-coagulation coating (ACC) on the migration rate of plasticizers from PVC tubing into blood. For the in-vitro study, five different groups of tubing sets in six replicates were perfused with sheep blood (Group A: PVC plasticized with di-(2-ethylhexyl) phthalate (DEHP) without ACC, Group B: DEHP-plasticized PVC with ACC, Group C: PVC plasticized with tri-(2-ethylhexyl) trimellitate (TOTM) without ACC, Group D: TOTM-plasticized PVC with ACC, Group E (control group): polyolefin material with ACC but without plasticizers). Both the levels of the unchanged plasticizers in blood and the concentration levels of their primary degradation products were assessed. For DEHP, the primary metabolite MEHP (mono-(2-ethylhexyl) phthalate) was determined. The isomers of MEHTM (mono-(2-ethylhexyl) trimellitate) and DEHTM (di-(2-ethylhexyl) trimellitate), respectively, were investigated as primary metabolites of TOTM. The calculated DEHP equivalents (sum of determined levels of DEHP and MEHP) after 24 h of perfusion displayed a tendency towards lower levels in the tubing sets without ACC (Group A (201 ± 56.4 μmol/L)) compared to the tubing sets with ACC (Group B (253 ± 369 μmol/L)). Significantly different DEHP equivalents between Group A and Group B were found after a perfusion time of 6 h and 10 h, respectively. A similar effect was observed for the TOTM-containing tubing sets. However, the absolute plasticizer migration rate of TOTM (TOTM equivalents) after 24 h of perfusion was found to be significantly lower compared to that of DEHP (with a factor of over 200). The results indicate that phospholipid coating (ACC) rather enhances the migration of plasticizers and of their primary degradation products from PVC tubing into streaming blood. The enhancement effect was found to be slightly greater for TOTM, but as TOTM migrates in significantly lower levels than DEHP in all experimental settings, TOTM is confirmed to be a recommendable alternative plasticizer to DEHP in medical devices.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blood management; DEHP; Hemocompatibility; Medical device; Patient safety; TOTM

Mesh:

Substances:

Year:  2018        PMID: 29604561     DOI: 10.1016/j.chemosphere.2018.03.136

Source DB:  PubMed          Journal:  Chemosphere        ISSN: 0045-6535            Impact factor:   7.086


  4 in total

1.  In vitro and in silico approach to study the hormonal activities of the alternative plasticizer tri-(2-ethylhexyl) trimellitate TEHTM and its metabolites.

Authors:  Laurence Dahbi; Amaury Farce; Nicolas Kambia; Isabelle Séverin; Thierry Dine; Emmanuel Moreau; Valérie Sautou; Marie-Christine Chagnon
Journal:  Arch Toxicol       Date:  2022-01-28       Impact factor: 5.153

2.  Exposure of patients to di(2-ethylhexy)phthalate (DEHP) and its metabolite MEHP during extracorporeal membrane oxygenation (ECMO) therapy.

Authors:  Franziska Kaestner; Frederik Seiler; Daniel Rapp; Elisabeth Eckert; Johannes Müller; Carlos Metz; Robert Bals; Hans Drexler; Philipp M Lepper; Thomas Göen
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

3.  A One-pot-synthesized Double-layered Anticoagulant Hydrogel Tube.

Authors:  Di Sun; Wenqing Gao; Peng Wu; Jie Liu; Shengmei Li; Shilin Li; Meili Yu; Meng Ning; Ru Bai; Tong Li; Ying Liu; Chunying Chen
Journal:  Chem Res Chin Univ       Date:  2021-09-04       Impact factor: 1.307

Review 4.  Biomimetic materials based on zwitterionic polymers toward human-friendly medical devices.

Authors:  Kazuhiko Ishihara
Journal:  Sci Technol Adv Mater       Date:  2022-09-13       Impact factor: 7.821

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.